Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
Profusa (NASDAQ:PFSA), a digital health company, has announced a significant commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. The partnership centers around the adoption of Profusa's Lumee Oxygen platform in Prof. Brodmann's practice, which conducts approximately 1,500 annual vascular procedures.
Prof. Brodmann, who previously served as PI for Lumee Oxygen's CE Mark clinical studies, will integrate the technology into her clinical practice and research programs. The collaboration aims to explore additional indications for Profusa's proprietary technology while providing real-time oxygen perfusion monitoring for patients with critical limb ischemia.
Profusa (NASDAQ:PFSA), azienda nel settore della salute digitale, ha annunciato una rilevante collaborazione commerciale e clinica con la Prof.ssa Dr. Marianne Brodmann dell'Università Medica di Graz, Austria. L'accordo riguarda l'adozione della Piattaforma Lumee Oxygen di Profusa nella pratica clinica della Prof.ssa Brodmann, che esegue circa 1.500 procedure vascolari all'anno.
La Prof.ssa Brodmann, che in passato è stata investigatrice principale per gli studi clinici del marchio CE di Lumee Oxygen, integrerà questa tecnologia nella sua attività clinica e nei programmi di ricerca. La collaborazione ha l'obiettivo di valutare ulteriori indicazioni per la tecnologia proprietaria di Profusa e di offrire monitoraggio in tempo reale della perfusione di ossigeno per pazienti con ischemia critica degli arti.
Profusa (NASDAQ:PFSA), una compañía de salud digital, ha anunciado una importante colaboración comercial y clínica con la Prof. Dra. Marianne Brodmann de la Universidad Médica de Graz, Austria. La alianza se centra en la adopción de la plataforma Lumee Oxygen de Profusa en la práctica de la Prof. Brodmann, la cual realiza aproximadamente 1.500 procedimientos vasculares al año.
La Prof. Brodmann, quien fue investigadora principal en los estudios clínicos para la marca CE de Lumee Oxygen, integrará la tecnología en su práctica clínica y en sus programas de investigación. La colaboración busca explorar nuevas indicaciones para la tecnología propia de Profusa y ofrecer monitorización en tiempo real de la perfusión de oxígeno en pacientes con isquemia crítica de las extremidades.
Profusa (NASDAQ:PFSA)는 디지털 헬스 기업으로, 오스트리아 그라츠 의과대학의 Prof. Dr. Marianne Brodmann와 중요한 상업적·임상 협력을 발표했습니다. 이번 제휴는 Profusa의 Lumee Oxygen 플랫폼을 Brodmann 교수의 진료에 도입하는 것을 중심으로 하며, 그녀의 진료 기관은 연간 약 1,500건의 혈관 시술을 시행하고 있습니다.
Brodmann 교수는 Lumee Oxygen의 CE 마크 임상시험에서 책임연구자(PI)를 맡은 바 있으며, 해당 기술을 임상 실무와 연구 프로그램에 통합할 예정입니다. 이번 협력은 Profusa의 독점 기술에 대한 추가 적응증을 모색하고, 말초동맥질환으로 인한 중증 하지 허혈 환자들에게 실시간 산소 관류 모니터링을 제공하는 것을 목표로 합니다.
Profusa (NASDAQ:PFSA), une entreprise de santé numérique, a annoncé une importante collaboration commerciale et clinique avec la Prof. Dr. Marianne Brodmann de l'Université médicale de Graz, en Autriche. Le partenariat porte sur l'adoption de la plateforme Lumee Oxygen de Profusa dans la pratique de la Prof. Brodmann, qui réalise environ 1 500 procédures vasculaires par an.
La Prof. Brodmann, qui a précédemment été investigatrice principale pour les études cliniques ayant conduit au marquage CE de Lumee Oxygen, intégrera cette technologie dans son activité clinique et ses programmes de recherche. La collaboration vise à explorer de nouvelles indications pour la technologie propriétaire de Profusa tout en fournissant une surveillance en temps réel de la perfusion en oxygène pour les patients atteints d'ischémie critique des membres.
Profusa (NASDAQ:PFSA), ein Unternehmen im Bereich digitale Gesundheit, hat eine bedeutende kommerzielle und klinische Zusammenarbeit mit Prof. Dr. Marianne Brodmann von der Medizinischen Universität Graz in Österreich bekanntgegeben. Die Partnerschaft fokussiert auf die Implementierung von Profusas Lumee Oxygen Plattform in der Praxis von Prof. Brodmann, die jährlich etwa 1.500 vaskuläre Eingriffe durchführt.
Prof. Brodmann, die zuvor als Prüferin (PI) für die CE‑Markt‑Klinikstudien von Lumee Oxygen tätig war, wird die Technologie in ihre klinische Tätigkeit und Forschungsprogramme integrieren. Die Zusammenarbeit zielt darauf ab, weitere Indikationen für Profusas proprietäre Technologie zu untersuchen und Patienten mit kritischer Extremitätenischämie eine Echtzeitüberwachung der Sauerstoffperfusion zu bieten.
- None.
- None.
Insights
Profusa's commercial collaboration with a prominent vascular specialist strengthens clinical validation and expands European market presence for their Lumee Oxygen platform.
Profusa's new collaboration with Prof. Dr. Marianne Brodmann represents significant clinical validation for their Lumee Oxygen monitoring platform. This partnership brings two substantial advantages: immediate commercial implementation across approximately
The credibility of this adoption is particularly noteworthy given Prof. Brodmann's extensive credentials, including her role as principal investigator for the Lumee platform's CE Mark studies and her positions with the European Society of Cardiology. Her involvement in over 50 international trials and authorship of more than 100 PubMed-indexed publications lends substantial weight to her endorsement of Profusa's technology.
For critical limb ischemia patients, real-time tissue oxygen monitoring addresses a crucial clinical need during both surgical procedures and recovery periods. The Lumee platform's continuous biochemical monitoring capabilities could become particularly valuable in vascular medicine where timely intervention decisions often depend on accurate perfusion data.
Beyond immediate implementation, this collaboration creates a pathway for Profusa to potentially expand approved use cases for their technology platform. By integrating into Prof. Brodmann's clinical studies, Profusa gains access to additional validation opportunities that could substantiate new applications, ultimately expanding their addressable market in Europe where the technology already holds CE Mark approval.
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs
BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. Under the collaboration, Prof. Brodmann will adopt the Lumee oxygen platform technology in her practice of approximately 1,500 annual vascular procedures. In addition, as principal investigator (PI) of clinical studies that supported Lumee oxygen in its CE marking, Prof. Brodmann intends to integrate Profusa’s platform technology in cases and clinical study programs.
"Real-time oxygen perfusion data for patients suffering from critical limb ischemia is critical for the proper monitoring of patients during surgery and as they recover," said Prof. Brodmann. "As an experienced user of Profusa's technology through leading portions of Profusa's clinical studies, I am convinced that the Lumee Oxygen platform meets an important clinical need. I am excited to adopt the Lumee Oxygen system to improve patient outcomes and continue to explore ways for clinical communities to use Lumee Oxygen to improve patient care."
Prof. Dr. Marianne Brodmann is a board member of the European Union of Medical Specialists and a fellow at the European Society of Cardiology (ESC). She served as the president of the Austrian Society of Angiology, a national delegate for the International Union of Angiology, and had been a member of various groups such as ESC Working Group on Aorta & Peripheral Vascular Diseases and Nucleus ÖGIA. She has been involved with more than 50 international trials, researching, among many topics, anticoagulation, thrombolysis, restenosis, and new technologies in the endovascular field. Prof. Brodmann has over 100 publications listed on PubMed Central.
"Our continued collaboration with Prof. Brodmann and the Medical University of Graz, Austria provides additional validation for our Lumee technology platform, and we are proud to add the practice to our commercial network,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “We also look forward to the integration of our platform technology into Prof. Brodmann’s cases and clinical studies in a drive for additional indications for use of our proprietary technology, expanding our market reach.”
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
FAQ
What is the purpose of Profusa's collaboration with Medical University of Graz?
Who is Prof. Dr. Marianne Brodmann and why is she significant for Profusa (PFSA)?
What is the Lumee Oxygen platform used for?
How will this collaboration benefit Profusa (PFSA)?
